|July 11, 2014|
|09:21 EDT||SRPT||RW Baird remains bullish on Sarepta after 144 week DMD data|
Baird said Sarepta's 144 week data for eteplirsen did not necessarily help reinforce its NDA filing, but the firm still thinks the drug's ability to delay disease progression is demonstrated by the data. The firm maintains its bullish view of the stock and keeps an Outperform rating and $53 price target on Sarepta.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
|July 25, 2014|
|09:57 EDT||SRPT||Sarepta CSO had 'serious disagreements' with CEO, WSJ reports|
Sarepta's recently terminated Chief Scientific Officer Arthur Krieg said he had "serious disagreements" with CEO Chris Garabedian, Wall Street Journal reported last night, citing comments from a phone interview. Krieg's termination follows other management departures and "interrupts" the process" of preparing eteplirsen paperwork for the FDA, the Journal added, citing a person familiar with the matter. Recall that The Street's Adam Feuerstein reported yesterday that Krieg had no role in the clinical development of eteplirsen. Reference Link
|July 24, 2014|
|09:37 EDT||SRPT||Sarepta fired CSO not involved in eteplirsen, The Street reports|
Sarepta's just fired Chief Scientific Officer Art Krieg had no role in the clinical development of eteplirsen, The Street's Adam Feuerstein reports, citing two sources familiar with the situation. Krieg's exit relates to Sarepta being behind schedule in bringing new drugs into the clinic, Feuerstein adds. Reference Link
|09:16 EDT||SRPT||On The Fly: Pre-market Movers|
Subscribe for More Information
|06:52 EDT||SRPT||Sarepta terminates Chief Scientific Officer Arthur Krieg|
Sarepta disclosed that on July 22, Arthur Krieg, M.D., the company's Chief Scientific Officer, was terminated from his position. No other information was provided in the regulatory filing disclosing the news.
|July 22, 2014|
|10:00 EDT||SRPT||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: Abengoa Yield (ABY) initiated with an Equal Weight at Morgan Stanley... Actinium Pharmaceuticals (ATNM) initiated with a Buy at Canaccord... Axys Technologies (AXYS) initiated with a Buy at Dougherty... Chambers Street Properties (CSG) initiated with a Neutral at SunTrust... Enphase Energy (ENPH) initiated with a Buy at Dougherty... Minerals Technologies (MTX) initiated with an Outperform at Wedbush... NextEra Energy Partners (NEP) initiated with a Buy at BofA/Merrill... PTC Therapeutics (PTCT) initiated with a Buy at BofA/Merrill... QIWI (QIWI) initiated with a Positive at Susquehanna... Quality Systems (QSII) initiated with a Buy at Topeka... Sarepta (SRPT) initiated with a Neutral at BofA/Merrill... Trinseo S.A. (TSE) initiated with a Buy at BofA/Merrill... Washington Prime Group (WPG) initiated with a Neutral at SunTrust... Zhaopin (ZPIN) initiated with a Buy at UBS.
|07:11 EDT||SRPT||Sarepta initiated with a Neutral at BofA/Merrill|
Subscribe for More Information